ENDP : Analysis & Opinions

  1. NPS Pharmaceuticals' Natpara Approved with Boxed Warning - Analyst ...

    January 27, 2015
    NPS Pharmaceuticals' (NPSP) Natpara gained FDA approval as an adjunct treatment to calcium and vitamin D to control hypocalcemia ...
  2. Endo International plc (ENDP): New Analyst Report from Zacks ...

    January 23, 2015
    Endo's third-quarter 2014 earnings of $1.15 per share beat the Zacks Consensus Estimate of $0.99 but decreased 14% from the ...
  3. Endo Prices $1.2B Senior Notes Offering for Auxilium Deal - Analyst ...

    January 22, 2015
    Endo International has priced $1.2 billion aggregate principal amount of 6.00% senior notes due Feb 2025 at par with a face ...
  4. ARIAD's Iclusig Endorsed by EC for All Approved Indications - ...

    January 21, 2015
    ARIAD Pharmaceuticals, Inc. (ARIA) announced that the European Commission endorsed the CHMP's recommendation on the use of ...
  5. Evotec Signs New Deal for Addictive Disorder Therapies - Analyst ...

    January 20, 2015
    Evotec AG (EVTCY) entered into a research collaboration agreement with C4X Discovery Holdings plc for the development of ...
  6. Novo Nordisk's Xultophy to Launch First in Switzerland - Analyst ...

    January 20, 2015
    Novo Nordisk A/S (NVO) announced that the company will first launch its combination diabetes drug, Xultophy, in Switzerland.
  7. OncoGenex's AFFINITY on Track, Passes Futility Analysis - Analyst ...

    January 19, 2015
    OncoGenex Pharmaceuticals, Inc. (OGXI) announced that the phase III AFFINITY study on custirsen has passed the interim futility ...
  8. UCB-Neuropore Collaborate for Parkinson's Disease Therapy - Analyst ...

    January 19, 2015
    UCB S.A. (UCBJF) and Neuropore Therapies Inc. entered into a collaboration agreement for the development and commercialization ...
  9. BioCryst's BCX4161 Recommended for Orphan Drug in EU - Analyst ...

    January 15, 2015
    BioCryst Pharmaceuticals, Inc. (BCRX) received a positive opinion regarding its application for orphan drug status for BCX4161 ...
  10. ARIAD Reveals 2015 Strategic Objectives, Updates on Pipeline ...

    January 14, 2015
    ARIAD Pharmaceuticals, Inc. (ARIA) announced its key strategic objectives for 2015 and its aim to increase R&D and expand ...
  11. Hospira's Dyloject Cleared in the U.S. for Pain Management - ...

    December 31, 2014
    The FDA has approved Hospira's (HSP) proprietary nonsteroidal anti-inflammatory drug analgesic, Dyloject.
  12. 4 Biotech Stocks that Doubled in 2014 - Analyst Blog

    December 26, 2014
    Promising pipeline candidates, progress on the regulatory front and interesting research platforms helped these 4 biotech ...
  13. Endo/BioDelivery File Regulatory Application for Pain Drug - ...

    December 24, 2014
    Endo International along with its partner BioDelivery Sciences International, Inc. announced the submission of a new drug ...
  14. Auxilium's Xiapex Gets CHMP Nod for Peyronie's Disease - Analyst ...

    December 23, 2014
    Auxilium Pharmaceuticals (AUXL) and partner Sobi's Xiapex is a step closer to EU approval with the CHMP giving a favorable ...
  15. 4 Top Ranked Biotech Stocks that Beat the Market in 2014 - Analyst ...

    December 16, 2014
    Despite the sell-off in late March, the biotech sector bounced back thanks to important product approvals, mergers and acquisitions, ...
  16. Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook

    November 18, 2014
    Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook
  17. ViroPharma and Other Biotech Stocks Recommended by Oppenheimer ...

    June 24, 2013
    Oppenheimer has a new team of analysts focused on biotechnology and specialty pharmaceuticals. And, research from the new ...
  18. Impax Launches Opana ER Generic - Analyst Blog

    January 7, 2013
    Global Pharmaceuticals, the generic division of Impax Laboratories, Inc. (IPXL), a specialty pharmaceutical company, recently ...
  19. Endo Health Solutions Needs Some Solutions Of Its Own

    November 7, 2012
    Can Endo reestablish itself as a quality healthcare name?
  20. Endo Health Beats on All Fronts - Analyst Blog

    August 9, 2012
    Endo Health Solutions' (ENDP) second quarter 2012 earnings (excluding special items) of $1.27 per share beat the Zacks Consensus ...
  21. The Salix Story Keeps Improving

    January 18, 2012
    Salix is a great candidate for growth investors.
  22. Endo And Forest – Dumpster-Diving In Pharma

    September 21, 2011
    Endo and Forest have problems; however, the valuations seem excessively low.
Trading Center